Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00357448 · ClinicalTrials.gov registry record · Phase 1
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00357448 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 11 participants.
The verdict
NCT00357448, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as denileukin difitox, may stimulate the immune system in different ways and may prevent tumor cells from growing. PURPOSE: This phase I trial is studying the side effects and best dose of denileukin diftitox in treating patients with advanced refractory ovarian cancer, primary peritoneal carcinoma, or epithelial fallopian tube cancer.
Interventions
- OTHER laboratory biomarker analysis
- OTHER flow cytometry
- OTHER enzyme-linked immunosorbent assay
- BIOLOGICAL denileukin diftitox
- PROCEDURE intraperitoneal administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00357448
The ClinicalTrials.gov registry entry for NCT00357448 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00357448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00357448 about?
NCT00357448 is a clinical study titled "Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer". RATIONALE: Biological therapies, such as denileukin difitox, may stimulate the immune system in different ways and may prevent tumor cells from growing. PURPOSE: This phase I trial is studying the side effects and best dose of denileukin diftitox in treating patients with advanced refractory ovarian...
What is the current status of trial NCT00357448?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2005-04.
What interventions are being tested in trial NCT00357448?
The interventions under investigation include: laboratory biomarker analysis (OTHER), flow cytometry (OTHER), enzyme-linked immunosorbent assay (OTHER), denileukin diftitox (BIOLOGICAL), intraperitoneal administration (PROCEDURE).
Who is sponsoring clinical trial NCT00357448?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.